Karen Marder, MD
Neurology · New York, NYNPI 1710057369
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,000 of the $2,598 with a category attached, or 77.0%. PTC Therapeutics, Inc. accounts for 77.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $2,000 and has fallen 74.6% since, to $507 in 2024.
Across 9 payments — averaging $288.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PTC Therapeutics, Inc.$2K
- Alnylam Pharmaceuticals Inc.$507
- Genentech USA, Inc.$91
Across 69 payments — averaging $20,824 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.1M
- F. Hoffmann-la Roche AG$233K
- Novartis$72K
- Alnylam Pharmaceuticals Inc.$14K
- Teva Pharmaceuticals USA, Inc.$13K
What the payments were for
- Consulting fees$2,00077%
- Travel & lodging$40616%
- Food & beverage$1927%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PTC Therapeutics, Inc. | 1 | $2,000 |
| Alnylam Pharmaceuticals Inc. | 7 | $507 |
| Genentech USA, Inc. | 1 | $91 |
How this compares
$2,598 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 16 | $144,081 |
| Rivastigmine | 31 | $7,093 |
| Galantamine ErGalantamine Hbr | 60 | $5,696 |
| Memantine Hcl ErMemantine Hcl | 63 | $2,148 |
| Escitalopram Oxalate | 121 | $1,918 |
| Donepezil Hcl | 155 | $1,807 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $888 |
| Olanzapine | 48 | $830 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 35 | $700 |
| Risperidone | 41 | $513 |
| Sertraline Hcl | 59 | $498 |
| Quetiapine Fumarate | 46 | $475 |
| Clomipramine Hcl | 14 | $470 |
| Clonazepam | 42 | $435 |
| Mirtazapine | 22 | $378 |
Paid to pharmacies, not to this prescriber.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.